Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 4

The impact of SHS exposure on health status and exacerbations among patients with COPD

Authors Mark D Eisner, Carlos Iribarren, Edward H Yelin, Stephen Sidney, et al.

Published 6 May 2009 Volume 2009:4 Pages 169—176

DOI http://dx.doi.org/10.2147/COPD.S4681

Review by Single-blind

Peer reviewer comments 2

Mark D Eisner1,3, Carlos Iribarren3, Edward H Yelin2, Stephen Sidney3, Patricia P Katz2, Gabriela Sanchez3, Paul D Blanc1

1Division of Occupational and Environmental Medicine and Division of Pulmonary and Critical Care Medicine; 2Institute for Health Policy Studies, Department of Medicine, University of California, San Francisco, CA, USA; 3Division of Research, Kaiser Permanente, Oakland, CA, USA

Abstract: Secondhand smoke (SHS) is a major contributor to indoor air pollution. Because it contains respiratory irritants, it may adversely influence the clinical course of persons with chronic obstructive pulmonary disease (COPD). We used data from nonsmoking members of the FLOW cohort of COPD (n = 809) to elucidate the impact of SHS exposure on health status and exacerbations (requiring emergency department visits or hospitalization). SHS exposure was measured by a validated survey instrument (hours of exposure during the past week). Physical health status was measured by the SF-12 Physical Component Summary Score and disease-specific health-related quality of life (HRQL) by the Airways Questionnaire 20-R. Health care utilization for COPD was determined from Kaiser Permanente Northern California computerized databases. Compared to no SHS exposure, higher level SHS exposure was associated with poorer physical health status (mean score decrement −1.78 points; 95% confidence interval [CI] −3.48 to −0.074 points) after controlling for potential confounders. Higher level SHS exposure was also related to poorer disease-specific HRQL (mean score increment 0.63; 95% CI 0.016 to 1.25) and less distance walked during the Six-Minute Walk test (mean decrement −50 feet; 95% CI −102 to 1.9). Both lower level and higher level SHS exposure was related to increased risk of emergency department (ED) visits (hazard ratio [HR] 1.40; 95% CI 0.96 to 2.05 and HR 1.41; 95% CI 0.94 to 2.13). Lower level and higher level SHS exposure were associated with a greater risk of hospital-based care for COPD, which was a composite endpoint of either ED visits or hospitalizations for COPD (HR 1.52; 95% CI 1.06 to 2.18 and HR 1.40; 95% CI 0.94 to 2.10, respectively). In conclusion, SHS was associated with poorer health status and a greater risk of COPD exacerbation. COPD patients may comprise a vulnerable population for the health effects of SHS.

Keywords: chronic obstructive pulmonary disease, chronic bronchitis, pulmonary emphysema, tobacco smoke pollution

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other article by this author:

COPD and cognitive impairment: the role of hypoxemia and oxygen therapy

Neeta Thakur, Paul D Blanc, Laura J Julian, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:263-269

Published Date: 10 August 2010

Readers of this article also read:

Arginine-vasopressin marker copeptin is a sensitive plasma surrogate of hypoxic exposure

Ostergaard L, Rudiger A, Wellmann S, Gammella E, Beck-Schimmer B, Struck J, Maggiorini M, Gassmann M

Hypoxia 2014, 2:143-151

Published Date: 11 September 2014

Pluronic® L64-mediated stable HIF-1α expression in muscle for therapeutic angiogenesis in mouse hindlimb ischemia

Song H, Liu S, Li C, Geng Y, Wang G, Gu Z

International Journal of Nanomedicine 2014, 9:3439-3452

Published Date: 21 July 2014

Cationic star-shaped polymer as an siRNA carrier for reducing MMP-9 expression in skin fibroblast cells and promoting wound healing in diabetic rats

Li N, Luo HC, Yang C, Deng JJ, Ren M, Xie XY, Lin DZ, Yan L, Zhang LM

International Journal of Nanomedicine 2014, 9:3377-3387

Published Date: 15 July 2014

A challenge to the seven widely believed concepts of COPD

Al-Kassmimi FA, Alhamad EH

International Journal of Chronic Obstructive Pulmonary Disease 2013, 8:21-30

Published Date: 14 January 2013

Safety of indacaterol in the treatment of patients with COPD

Donohue JF, Singh D, Kornmann O, Lawrence D, Lassen C, Kramer B

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:477-492

Published Date: 22 September 2011

COPD is frequent in conditions of comorbidity in patients treated with various diseases in a university hospital

Akira Yamasaki, Kiyoshi Hashimoto, Yasuyuki Hasegawa, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:351-355

Published Date: 29 September 2010

Clinical utility of varenicline for smokers with medical and psychiatric comorbidity

Jon O Ebbert, Kirk D Wyatt, Ali Zirakzadeh, et al

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:421-430

Published Date: 17 November 2009

Tiotropium HandiHaler® in the treatment of COPD: A safety review

Steven Kesten, Bart Celli, Marc Decramer, et al

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:397-409

Published Date: 28 October 2009

Management of invasive aspergillosis in patients with COPD: rational use of voriconazole

Florence Ader, Anne-Lise Bienvenu, Blandine Rammaert, et al.

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:279-287

Published Date: 24 July 2009